Immunotherapy & Vaccine Development

Monophosphoryl Lipid A (MPL) Adjuvants

Vaccine adjuvants using heterogeneous monophosphoryl Lipid A (MPL) derived from Salmonella minnesota R595 have proven to be safe and effective at inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines. Avanti revolutionized immunotherapy and vaccine development with the introduction of Synthetic MPL derivatives and adjuvant systems. Avanti now manufactures multiple synthetic analogs of MPL containing a single molecular species that are as effective and safe at inducing an immune response as their natural product predecessor. PHAD®, 3D-PHAD®, and 3D(6A)-PHAD® are manufactured according to cGMP guidelines and are available in bulk quantities for your clinical trials.

Licensing opportunities are available for your field of use. Please contact us at (205) 663-2494 for more information.

Adjuvant Systems

Is your immunotherapy or vaccine program spending valuable time and resources on adjuvant formulation development? With nearly 100 years of combined experience formulating lipids, Avanti can support your adjuvant formulation development activities. We offer formulation services for both pre-clinical and clinical development using our own cGMP manufactured lipids. Batches can be scaled from a few milliliters to >100 liters to accommodate your stage of clinical development. We work closely with your packaging group throughout the process to ensure we provide material suitable for aseptic fill/finish in your final dosage form for clinical trial. When you are ready for commercialization, Avanti can work in partnership with your CMO to provide a seamless transfer of the formulation for scale-up and manufacturing.

Adjuvant Activity

PHAD®, 3D-PHAD®, and 3D(6A)-PHAD® have been tested extensively in animals using a variety of antigens. In all cases, these adjuvants exhibit a similar activity and safety profile to bacterially-derived MPL. The data below demonstrate the equivalency of the three synthetic adjuvants to the bacterially-derived MPL when presented in a liposomal carrier system (DMPC/DMPG/Cholesterol).

Synthetic Lipid A